Protein chip-based dipeptidyl peptidase IV assay system

Biochip Journal

Volumn 3, Issue 3, 2009, Pages 249-253

  Kim, Eung Yoon ^a,b   Kang, In Cheol ^a,b  

^a Hoseo University   (South Korea)

^b Innopharmascreen Inc   (South Korea)

Author keywords

Diabetes inhibitor; DPP IV; Galvus; Protease assay

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70350336687     PISSN: 19760280     EISSN: 20927843     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mentlein, R. Dipeptidyl-peptidase IV(CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24(1999).
2. Yaron, A. & Naider, F. Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28, 31-81(1993).
3. Scanlan, M.J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA 91, 5657-5661(1994).
4. Demuth, H.-U. & Heins, J. in Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response ed. Fleischer, B.(R.G. Landes, Austin, TX), 1-35(1995).
5. Drucker, D.J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Exp. Opin. Invest. Drugs 12, 87-100(2003).
6. Hoffmann, T. et al. in Cell-Surface Aminopeptidases: Basic and Clinical Aspects, eds. Mizutani, M., Turner, A.J., Nomura, S., Ino, K. & Matsuo, M. (Elsevier, Amsterdam), 381-393(2001).
7. Hoffmann, T. & Demuth, H.-U. in Ectopeptidases: CD13_Aminopeptidase N and CD26_Dipeptidylaminopeptidase IV in Medicine and Biology, eds. Langner, J. & Ansorge, S. (Kluwer Academic_Plenum, New York), 259-278(2002).
8. Pederson, R.A. et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47, 1253-1258(1998).
9. Pospisilik, J.A., Stafford, S.G., Demuth, H.U., McIntosh, C.H. & Pederson, R.A. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51, 2677-2683(2002).
10. Ahren, B., Holst, J.J., Martensson, H. & Balkan, B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 404, 239-245(2000).
11. Deacon, C.F., Hughes, T.E. & Joist, J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47, 764-769 (1998).
12. Pospisilik, J.A. et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51, 943-950(2002).
13. Deacon, C.F. & Holst, J.J. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int. J. Biochem. Cell Biol. 38, 831-844(2006).
14. Triplitt, C., Wright, A. & Chiquett, E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 26, 360-374(2006).
15. Hunziker, D., Hennig, M. & Peters, J. Inhibitors of dipeptidyl peptidase IV-recent advances and structural views. Curr. Top. Med. Chem. 5, 1623-1637(2005).
16. Knudsen, L.B. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 47, 4128-4134(2004).
17. Holst, J.J. & Deacon, E.F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 4, 589-596(2004).
18. Drucker, D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122, 531-544(2002).
19. Kieffer, T.J., McIntosh, C.H. & Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596(1995).
20. Deacon, C.F. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44, 1126-1131(1995).